Helius Medical Technologies

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Helius Medical Technologies reports Q1 revenue, eyes CMS reimbursement boost

Helius Medical Technologies navigated Q1 2024 with a focus on reimbursement, FDA approval, and financial sustainability, supported by financing and market expansion initiatives.
Progress in securing reimbursement, expanding market reach, and addressing demand signals growth potential and market acceptance for the company's products.
Challenges in achieving profitability and executing development plans underscore the importance of timely reimbursement and effective operational strategies.

Helius Medical Technologies navigates revenue challenges with strategic growth initiatives

Helius Medical Technologies faces challenges from program terminations impacting revenue and ongoing operating losses, but maintains a strong cash position with no debt.
Efforts to expand access to PoNS Therapy through strategic partnerships and sales initiatives present growth opportunities in the MS and stroke treatment markets.
The company's financial performance in Q2 2024 reflects a mixed picture of revenue decline, operational losses, and cash stability, with potential for growth pending reimbursement determinations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

The stock price of Helius Medical Technologies Inc (NASDAQ: HSDT) is trading at over 14% pre-market. This is why it happened.

HSDT Stock Price Increases Over 14% Pre-Market: Why It Happened

NEWTOWN, Pa., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that fourth quarter and fiscal year 2020 financial results will be released after the market closes on Wednesday, March 10th.

Helius Medical Technologies to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 10, 2021

NEWTOWN, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today the closing of an underwritten public offering of units for gross proceeds of approximately $11.0 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Helius.

Helius Medical Technologies, Inc. Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

NEWTOWN, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today provided comments in response to a press release issued by the Centers for Medicare & Medicaid Services (“CMS”) on Tuesday, January 12, 2021.

Helius Medical Technologies, Inc. Comments on the Centers for Medicare & Medicaid Services' Announcement Regarding New Medicare Coverage Pathway for Breakthrough Medical Devices

The Company's Stock Will Continue to be Listed and Traded on The Nasdaq Stock Market

Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards

NEWTOWN, Pa., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the Noble Capital Markets 17th Annual Small & Microcap Investor Conference, which is being held virtually from January 19th-20th. Management will present on Tuesday, January 19th at 11:15 a.m. Eastern Time.

Helius Medical Technologies, Inc. to Present at the Noble Capital Markets 17th Annual Small & Microcap Investor Conference

Submits formal response to the U.S. Food and Drug Administration's request for additional information Submits formal response to the U.S. Food and Drug Administration's request for additional information

Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS™ Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis

NEWTOWN, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, is issuing this news release in light of unusual trading activity related to the shares of Class A Common Stock of Helius (the "Shares") on the Toronto Stock Exchange and The Nasdaq Capital Market. In view of such activity, The Nasdaq Capital Market and the Investment Industry Regulatory Organization of Canada (IIROC) on behalf of the Toronto Stock Exchange contacted the Company in accordance with their usual practice. While Helius does not normally comment on market activity, Helius confirms that it is not aware of any undisclosed material change in the business, operations or affairs of Helius that would account for the recent increase in trading activity, and related increase in trading price, of the Shares on the Toronto Stock Exchange and The Nasdaq Capital Market. Helius notes that this afternoon it is first making available an investor presentation, by furnishing the slides on a Current Report on Form 8-K, in connection with its planned participation at investor conferences in January, which conference participation was announced by press release on January 4, 2021.

Helius Medical Technologies, Inc. Comments on Unusual Market Activity

NEWTOWN, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences in January:

Helius Medical Technologies, Inc. to Present at Four Upcoming Investor Conferences in January

NEWTOWN, Pa., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today a 1-for-35 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time today. Beginning on January 4, 2021, the Company's common stock will trade on The Nasdaq Capital Market and the Toronto Stock Exchange on a split adjusted basis.

Helius Medical Technologies, Inc. Announces Reverse Stock Split

Helius Medical Technologies' (HSDT) Management on Q3 2020 Results - Earnings Call Transcript

NEWTOWN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences:

Helius Medical Technologies, Inc. to Present at Upcoming Investor Conferences in November

New clinics increase access to PoNS Treatment in population-dense areas across Canada New clinics increase access to PoNS Treatment in population-dense areas across Canada

Helius Medical Technologies, Inc. Announces the Expansion to a Total of 27 Authorized PoNS Treatment™ Clinic Locations Across Canada

NEWTOWN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that third quarter of fiscal year 2020 financial results will be released after the market closes on Thursday, November 12th.

Helius Medical Technologies to Release Third Quarter of Fiscal Year 2020 Financial Results on November 12, 2020

NEWTOWN, Pa., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that it has closed its previously announced private placement for total gross proceeds of approximately $3.4 million. The private placement consisted of an aggregate of 6,567,868 shares of the Company's Class A Common Stock, or common stock, and warrants to purchase an aggregate of 3,283,936 shares of common stock, at a purchase price of $0.52 per unit, consisting of one share of common stock and a warrant to purchase 0.50 shares of common stock, which aggregate share amounts reflect corrections to the previously announced numbers. The warrants have an exercise price of $0.452 per share of common stock and are exercisable for a period of three years from the date of issuance. Helius intends to use the net proceeds from the offering for funding operations, working capital and general corporate purposes.

Helius Medical Technologies Announces Closing of $3.4 Million Private Placement

NEWTOWN, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that it has entered into a securities purchase agreement for a private placement with a select group of accredited investors. The private placement will consist of an aggregate of 6,664,022 shares of the Company's Class A Common Stock, or common stock, and warrants to purchase an aggregate of 3,332,013 shares of common stock, at a purchase price of $0.52 per unit, consisting of one share of common stock and a warrant to purchase 0.50 shares of common stock, resulting in total gross proceeds of approximately $3.4 million. The warrants have an exercise price of $0.452 per share of common stock and will be exercisable for a period of three years from the date of issuance.

Helius Medical Technologies Announces $3.4 Million Private Placement

NEWTOWN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has received a request for additional information from the U.S. Food and Drug Administration (the “FDA” or “Agency”) related to the Company's request for de novo classification and clearance of the Portable Neuromodulation Stimulator (PoNS™) device as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis (“MS”), to be used as an adjunct to a supervised therapeutic exercise program in patients over 18 years of age.

Helius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and Clearance of the PoNS™ Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis

NEWTOWN, Pa., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced a partnership with Breakthrough Health (“Breakthrough”), a Berlin-based technology company. Breakthrough builds privacy-focused applications that empower people living with chronic disease to gather and securely own their healthcare data, with the opportunity to share it to support research.

Helius Medical Technologies, Inc. Announces Partnership with Breakthrough Health for Multiple Sclerosis Insights

Leading Multiple Sclerosis Experts to Inform U.S. Launch Planning and Market Access Strategies Leading Multiple Sclerosis Experts to Inform U.S. Launch Planning and Market Access Strategies

Helius Medical Technologies, Inc. Announces Formation of Multiple Sclerosis Scientific Advisory Board

NEWTOWN, Pa., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the publication of an important, peer-reviewed study titled Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderate Traumatic Brain Injury. The study was published in the peer reviewed journal EMJ Radiology. 2020;1[1]:64-71.

Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderat

NEWTOWN, Pa., Aug.  31, 2020  (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences in September:

Helius Medical Technologies, Inc. to Present at Three Upcoming Investor Conferences in September

NEWTOWN, Pa., Aug.  25, 2020  (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Philippe Deschamps, has stepped down from his positions as President and Chief Executive Officer (“CEO”) and resigned his position as Chairman of the Board of Directors, effective August 23, 2020. Current members of the Board of Directors, Dane C. Andreeff and Blane Walter, have been appointed to the respective positions of Interim President and CEO, effective August 23, 2020, and Chairman of the Board of Directors, effective August 23, 2020. Mr. Andreeff will continue to serve as a director of the Company and is expected to serve as Interim President and CEO until the Board of Directors completes its search for a permanent successor.

Helius Medical Technologies, Inc. Announces Departure of President, Chief Executive Officer and Chairman Philippe Deschamps; Board of Directors Appoints Dane C.

Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q2 2020 Results - Earnings Call Transcript

NEWTOWN, Pa., Aug.  12, 2020  (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended June 30, 2020.

Helius Medical Technologies, Inc. Reports Second Quarter of Fiscal Year 2020 Financial Results

NEWTOWN, Pa., Aug.  10, 2020  (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that second quarter of fiscal year 2020 financial results will be released after the market closes on Wednesday, August 12th.

News for Helius Medical Technologies Stock (HSDT)